BUSINESS WIRE: Samsung Electronics Begins Mass Production At New EUV Manufacturing Line

20.02.2020, 11:12 Uhr

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

Samsung's EUV capacity under 7nm will triple by end of 2020

To start shipping first 7 and 6nm-based mobile chips from V1 line in 1Q

SEOUL, South Korea --(BUSINESS WIRE)-- 20.02.2020 --

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that its new cutting-edge semiconductor fabrication line in Hwaseong, Korea, has begun mass production.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200220005359/en/

Anzeige

The facility, V1, is Samsung's first semiconductor production line dedicated to the extreme ultraviolet (EUV) lithography technology and produces chips using process node of 7 nanometer (nm) and below. The V1 line broke ground in February 2018, and began test wafer production in the second half of 2019. Its first products will be delivered to customers in the first quarter.

"Along with technology leadership and design infrastructure, manufacturing excellence is one of the most important elements of the foundry business," said Dr. ES Jung, President and Head of Foundry Business at Samsung Electronics. "As we ramp up production, the V1 line will enhance our ability to respond to market demand and expand opportunities to support our customers."

The V1 line is currently producing state-of-the-art mobile chips with 7 and 6nm process technology and will continue to adopt finer circuitry up to the 3nm process node.

By the end of 2020, the cumulative total investment in the V1 line will reach USD 6 billion in accordance with Samsung's plan and the total capacity from 7nm and below process node is expected to triple from that of 2019. Together with the S3 line, the V1 line is expected to play a pivotal role in responding to fast-growing global market demand for single-digit node foundry technologies.

As semiconductor geometries grow smaller, the adoption of EUV lithography technology has become increasingly important, as it enables scaling down of complex patterns on wafers and provides an optimal choice for next-generation applications such as 5G, AI, and Automotive.

With the V1 line in operation, Samsung now has a total of six foundry production lines in South Korea and the United States, including five 12-inch lines and one 8-inch line. (see below)

* Global manufacturing sites of Samsung foundry

Name

6-Line

S1-Line

S2-Line

S3-Line

S4-Line

V1-Line

Nodes

180~65nm

65~8nm

65~11nm

10nm~

65nm~

7nm~

Location

Giheung, Korea

Austin, USA

Hwaseong, Korea

Wafer Size

8-inch

12-inch

# # #

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com. 

Ujeong Jahnke

Samsung Semiconductor Europe GmbH

Tel. +49(0)6196-66-3300

Email: ujeong.j@samsung.com

Weitere Nachrichten

02.04. IRW-PRESS: True Leaf Brands Inc.: True Leaf stellt Antrag auf Aussetzung des Gläubigerverfahrens
02.04. BUSINESS WIRE: VDX.tv startet weltweite PSA-Initiative per Digitalvideo zur Information der Öffentlichkeit über COVID-19
02.04. BUSINESS WIRE: GN Hearing geht Partnerschaft mit Hörgeräte-Experten ein, um revolutiojnäre Telemedizin-Lösung auf den Markt zu bringen – neuer innovativer Zugang zu Hörgeräten und medizinischer Versorgung zu Hause
02.04. BUSINESS WIRE: Kostenlose Fernüberwachungslösung jetzt für alle klinischen Forschungsstandorte verfügbar
02.04. IRW-PRESS: First Mining Gold Corp. : First Mining meldet Änderungen im Board und Ernennung von Vice President, Investor Relations
02.04. BUSINESS WIRE: Im Rahmen einer globalen Partnerschaft mit Nestlé Health Science initiiert VALBIOTIS die zulassungsrelevante letzte Phase der klinischen Entwicklung von TOTUM-63
02.04. BUSINESS WIRE: CSC übernimmt die TCS-Groep in den Niederlanden
02.04. IRW-PRESS: Algernon Pharmaceuticals Inc.: Algernon informiert über den aktuellen Stand der Phase-II-Tests zu Ifenprodil für den Einsatz bei COVID-19
02.04. BUSINESS WIRE: P&G Joins Forces with the Red Cross and Red Crescent Network to Provide Emergency Relief and Serve European Communities During COVID-19 Pandemic
02.04. BUSINESS WIRE: RELIEF THERAPEUTICS Holding SA gibt den Abschluss eines Vertrags über den Aktientausch mit Sonnet BioTherapeutics Inc. für den Verkauf ihrer hundertprozentigen Tochtergesellschaft Relief Therapeutics SA bekannt
Anzeige
Anzeige